应用细胞免疫治疗肝细胞癌的研究  

Study on Cellular Immunotherapy for Hepatocellular Carcinoma

作　　者：蒙建源 朱刚健 MENG Jian-yuan;ZHU Gang-jian(Zone 1 of General Surgery Department,Wuzhou Gongren Hospital,Wuzhou 543000,Guangxi,China)

机构地区：[1]梧州市工人医院普外科一区,广西梧州543000

出　　处：《医学信息》2023年第5期177-180,共4页Journal of Medical Information

摘　　要：肝细胞癌为我国常见恶性肿瘤,其发病机制多变、异质性高、预后差,具有较高致死风险,除去常规治疗外,细胞免疫治疗已成为该病的重要研究方向。近年来,多项免疫疗法在HCC治疗中展现了良好的应用前景,包括肿瘤疫苗、免疫检查点抑制剂、过继性细胞免疫治疗、细胞因子、溶瘤病毒与溶瘤细菌等,其作用机制各异,为HCC的临床治疗提供了更多可能。现本文就当前HCC细胞免疫治疗的研究进展进行综述。Hepatocellular carcinoma(HCC)is a common malignant tumor in China.Its pathogenesis is variable,with high heterogeneity,poor prognosis and high risk of death.In addition to conventional treatment,cell immunotherapy has become an important research direction of the disease.In recent years,a number of immune therapies have shown good application prospects in the treatment of HCC,including tumor vaccines,immune checkpoint inhibitors,adoptive cellular immunotherapy,cytokines,oncolytic viruses and oncolytic bacteria,etc.,with different mechanisms of action,providing more possibilities for the clinical treatment of HCC.This article reviews the current research progress of HCC cell immunotherapy.

关 键 词：肝细胞癌 肿瘤疫苗 免疫检查点抑制剂 过继性细胞免疫治疗 细胞因子 

分 类 号：R735.7[医药卫生—肿瘤]